Bone-seeking radiopharmaceuticals are frequently used as diagnostic agents in nuclear medicine, because they can detect bone disorders before anatomical changes occur. Furthermore, their effectiveness in the palliation of metastatic bone cancer pain has been demonstrated in the clinical setting. With the aim of developing superior bone-seeking radiopharmaceuticals, many compounds have been designed, prepared, and evaluated. Here, several well-designed bone-seeking compounds used for diagnostic and therapeutic use, having the concept of radiometal complexes conjugated to carrier molecules to bone, are reviewed. © 2015 Kazuma Ogawa and Atsushi Ishizaki
The relative Insensitivity of standard radiological methods in the diagnosis of early metastatic dis...
Bone metastasis is a common sequelae of solid malignant tumors such as prostate, breast, lung, and r...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Copyright © 2015 K. Ogawa and A. Ishizaki. This is an open access article distributed under the Crea...
Bone-seeking therapeutic radiopharmaceuticals are utilized on the basis of the radionuclide?s partic...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
AIM: The aim of the study was to assess the state of the art of the use of bone-seeking radiopharmac...
Thesis (Ph.D. (Pharmacology))--North-West University, Potchefstroom Campus, 2006This thesis covers r...
Item does not contain fulltextTherapeutic phosphonate-based radiopharmaceuticals radiolabeled with b...
Radionuclide therapy has been an integral part of systemic treatment of patients with advanced and d...
ABSTRACT: Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphon...
Intractable bone pain secondary to bone metastasis from prostate or breast cancer, or other malignan...
The radionuclide bone scan is becoming increasingly useful for evaluating a wide variety of bone and...
Intractable bone pain secondary to bone metastasis from prostate or breast cancer, or other malignan...
Abstract only availablePhosphonate ligands labeled with radioisotopes decaying by beta emissions hav...
The relative Insensitivity of standard radiological methods in the diagnosis of early metastatic dis...
Bone metastasis is a common sequelae of solid malignant tumors such as prostate, breast, lung, and r...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Copyright © 2015 K. Ogawa and A. Ishizaki. This is an open access article distributed under the Crea...
Bone-seeking therapeutic radiopharmaceuticals are utilized on the basis of the radionuclide?s partic...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
AIM: The aim of the study was to assess the state of the art of the use of bone-seeking radiopharmac...
Thesis (Ph.D. (Pharmacology))--North-West University, Potchefstroom Campus, 2006This thesis covers r...
Item does not contain fulltextTherapeutic phosphonate-based radiopharmaceuticals radiolabeled with b...
Radionuclide therapy has been an integral part of systemic treatment of patients with advanced and d...
ABSTRACT: Bone-seeking radionuclides including samarium-153 ethylene diamine tetramethylene phosphon...
Intractable bone pain secondary to bone metastasis from prostate or breast cancer, or other malignan...
The radionuclide bone scan is becoming increasingly useful for evaluating a wide variety of bone and...
Intractable bone pain secondary to bone metastasis from prostate or breast cancer, or other malignan...
Abstract only availablePhosphonate ligands labeled with radioisotopes decaying by beta emissions hav...
The relative Insensitivity of standard radiological methods in the diagnosis of early metastatic dis...
Bone metastasis is a common sequelae of solid malignant tumors such as prostate, breast, lung, and r...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...